How lysophosphatidic acid affects immune T cell activation and function
Lysophosphatidic Acid Regulation of CD8 T cell activation and function
This study is looking at how a substance called lysophosphatidic acid (LPA) affects a type of immune cell called CD8 T cells, which help our bodies fight infections and cancer, to find ways to improve treatments for these conditions.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Colorado Denver NIH-funded |
| Lab location | 1 site (Aurora, UNITED STATES) |
| Project ID | NIH-10786085 on NIH RePORTER |
What this research studies
This research investigates the role of lysophosphatidic acid (LPA) in regulating the activation and function of CD8 T cells, which are crucial for fighting infections and tumors. By examining how LPA interacts with T cell receptors, the study aims to understand how this lipid influences T cell responses during infections and cancer. The research involves both human and mouse T cells to explore the mechanisms of TCR signaling and the effects of LPA on T cell proliferation and cytotoxic activity. Patients may benefit from insights that could lead to improved immune therapies targeting infections and cancers.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with bacterial infections or cancers that may benefit from enhanced T cell activity.
Not a fit: Patients with non-immunological conditions or those not affected by infections or cancers may not receive any benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic strategies that enhance the immune response against infections and tumors.
How similar studies have performed: Previous research has shown promising results in understanding T cell regulation, suggesting that this approach could yield significant insights.
Where this research is happening
Aurora, UNITED STATES
- University of Colorado Denver — Aurora, United States (Active)
Researchers
- Principal investigator: Torres, Raul Martin — University of Colorado Denver
- Study coordinator: Torres, Raul Martin
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.